Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193846 | 0.83 | PDE1B (0.59) | ALDH1A1POLBNPBWR1PIK3CDMEN1 | |
| SCHEMBL3008452 | 0.81 | NPBWR1 (0.46) | ALDH1A1POLBNPBWR1PIK3CDMEN1 | |
| SCHEMBL3089382 | 0.78 | PIK3CD (0.53) | ALDH1A1POLBNPBWR1PIK3CDMEN1 | |
| SCHEMBL18330058 | 0.76 | ALDH1A1 (0.49) | ALDH1A1POLBNPBWR1PIK3CDMEN1 | |
| SCHEMBL3091849 | 0.76 | PDE1B (0.54) | NPBWR1MEN1KMT2AADORA3HPGD | |
| SCHEMBL23069655 | 0.75 | PDE1B (0.57) | ALDH1A1POLBNPBWR1MEN1KMT2A | |
| SCHEMBL29790114 | 0.75 | PDE1B (0.57) | ALDH1A1POLBNPBWR1MEN1KMT2A | |
| SCHEMBL19159223 | 0.74 | ADORA2B (0.37) | ALDH1A1POLBMEN1KMT2AADORA3 | |
| SCHEMBL193943 | 0.74 | PDE1B (0.60) | ALDH1A1POLBNPBWR1PIK3CDMEN1 | |
| SCHEMBL17508430 | 0.74 | NPBWR1 (0.45) | ALDH1A1POLBNPBWR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888534-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9624230-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150197528-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2015-07-16 | — | — | US | disclosed |
| EP-2358723-B1 | 4,5,7,8-tetrahydro-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors | INTRA CELLULAR THERAPIES INC (US) | 2015-05-13 | — | — | EP | disclosed |
| US-9000001-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20150080357-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2015-03-19 | — | — | US | disclosed |
| US-8633180-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20140011783-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20130018063-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2013-01-17 | — | — | US | disclosed |
| US-8273750-B2 | 7,8-dihydro-[1H or 2H]-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, substituted at the 1 or 2 position with C2-]alkyl, C3-9 cycloalkyl, heteroarylalkyl, or arylalkyl; phosphodiesterase 1 inhibitors; Parkinsons disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120071450-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2012-03-22 | — | — | US | disclosed |
| EP-2358723-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010065151-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20080188492-A1 | 7,8-dihydro-[1H or 2H]-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, substituted at the 1 or 2 position with C2-]alkyl, C3-9 cycloalkyl, heteroarylalkyl, or arylalkyl; phosphodiesterase 1 inhibitors; Parkinsons disease | INTRA-CELLULAR THERAPIES, INC (US) | 2008-08-07 | — | — | US | disclosed |
| EP-1888534-A2 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006133261-A2 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197528-A1 | ORGANIC COMPOUNDS | PDE3A, PDE9A, PDE2A | ALDH1A1 122/4885POLB 1472/4885NPBWR1 3936/4885 |
| US-20140011783-A1 | ORGANIC COMPOUNDS | TYMS, TPMT, THPO | ALDH1A1 215/4885POLB 558/4885NPBWR1 4829/4885 |
| US-20130018063-A1 | ORGANIC COMPOUNDS | PDE9A, PDE3A, PDE7A | ALDH1A1 95/4885POLB 1233/4885NPBWR1 3757/4885 |
| US-20080188492-A1 | 7,8-dihydro-[1H or 2H]-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, substituted at the 1 or 2 position with C2-]alkyl, C3-9 cycloalkyl, heteroarylalkyl, or arylalkyl; phosphodiesterase 1 inhibitors; Parkinsons disease | PDE9A, PDE3A, PDE7A | ALDH1A1 110/4885POLB 1155/4885NPBWR1 3426/4885 |
| US-20120071450-A1 | ORGANIC COMPOUNDS | TYMS, TPMT, THPO | ALDH1A1 215/4885POLB 558/4885NPBWR1 4829/4885 |
| US-20150080357-A1 | ORGANIC COMPOUNDS | TYMS, TPMT, THPO | ALDH1A1 215/4885POLB 558/4885NPBWR1 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.